top of page

A New Age of
CNS Solutions

Our Projects

Cloud Analytics Modernization

I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. I’m a great place for you to tell a story and let your users know a little more about you.

A Staggered approach to IP creation 

We Combine the power of psychedelics with our development capabilities and collaborations with top tear research institutes to create a robust pipeline of new indications, novel formulations and new third generation molecules. This creates a staggered approach to ensure longevity and innovation. Aging population, Covid-19 and a global need for opioid replacements makes our mission one of the most needed in the coming future.

2560px-UC_Davis_wordmark_edited.png

University Of California 

HadassahBrainLabs_Logo_S1_edited_edited.png

New Neurological indications  (use case IP \ Formulation IP) 

The surge in psychedelic research and wide acceptance from regulators and the medical community opens the opportunity to promote human clinical trials in new previously un explored indications. Getting real world clinical efficacy data is an un paralleled opportunity to discover new neurological indications affected by psychedelic treatment as well as educate our R&D efforts to be able to create better second generation solutions.  

Learn more about our indications
mindmed_edited.png
favpng_technion-israel-institute-of-technology-weizmann-institute-of-science-school_edited

Drug Delivery (Delivery \ CoM IP)  

IMIO’s Brain Targeted Liposome System (BTLs) was developed together with the Israel Institute of Technology to enable targeted drug delivery across the Blood Brain Barrier  BBB. It has the ability to actively transport  drugs through the BBB and into the brain. Extensive pre-clinical work  has demonstrated BBB penetration ability. Targeted delivery of medications to the brain brings the possibility to reduce side effects, reduce needed concentrations and manipulate the drug kinetics.

hewbrewu copy.png

The Hebrew
University
Of Jerusalem

Drug Discovery (CoM IP) 

Leveraging pre-clinical and clinical research data on mode of action and various effects of  known psychedelic drugs (i.e. 5-MeO-DMT or LSD), IMIO in collaboration with  Hebrew university's Institute for Drug Research to develop next generation of new chemical entities (NCE's) leveraging on Hebrew University's "Multi Targeting drug discovery platform" 

 

Successful NCEs deliver better care for patients and deliver the highest rate of return for investment in R&D and regulatory.

 

shutterstock_710229949_edited.jpg

IM-CRP

Fibromyalgia 

Cluster Headache 

IM-MCI

MCI

IM-CFS

Chronic  Fatigue 

BTLs

BTLs

shutterstock_710229949_edited.jpg

High Impact Chronic Pain 

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way the brain processes pain signals.Symptoms sometimes begin after a physical trauma, surgery, infection or significant psychological stress. In other cases, symptoms gradually accumulate over time with no single triggering event. Women are more likely to develop fibromyalgia than are men. Many people who have fibromyalgia also have tension headaches, temporomandibular joint (TMJ) disorders, irritable bowel syndrome, anxiety and depression.

20%

Estimated US Patients 

20%

Of US Population

3B$

Treatment  Market

shutterstock_710229949_edited.jpg

Fibromyalgia 

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Researchers believe that fibromyalgia amplifies painful sensations by affecting the way the brain processes pain signals.Symptoms sometimes begin after a physical trauma, surgery, infection or significant psychological stress. In other cases, symptoms gradually accumulate over time with no single triggering event. Women are more likely to develop fibromyalgia than are men. Many people who have fibromyalgia also have tension headaches, temporomandibular joint (TMJ) disorders, irritable bowel syndrome, anxiety and depression.

10M

Estimated US Patients 

3-6%

World Population

3B$

Treatment  Market

shutterstock_710229949_edited.jpg

Cluster Headaches 

Cluster headaches, which occur in cyclical patterns or cluster periods, are one of the most painful types of headache. A cluster headache commonly awakens you in the middle of the night with intense pain in or around one eye on one side of your head. Bouts of frequent attacks, known as cluster periods, can last from weeks to months, usually followed by remission periods when the headaches stop. A cluster period generally lasts for several weeks to months. The starting date and the duration of each cluster period might be consistent from period to period. Most people have episodic cluster headaches. In episodic cluster headaches, the headaches occur for one week to a year, followed by a pain-free remission period lasting 3 months or longer before another cluster headache develops.

10M

Estimated US Patients 

3-6%

World Population

1B$

Treatment  Market

shutterstock_710229949_edited.jpg

Chronic Fatigue Syndrome (CFS) 

Chronic fatigue syndrome (CFS) is a complicated disorder characterized by extreme fatigue that lasts for at least six months and that can't be fully explained by an underlying medical condition. The fatigue worsens with physical or mental activity, but doesn't improve with rest. Anyone can get CFS. While most common in people between 40 and 60 years old, the illness affects children, adolescents, and adults of all ages. Among adults, women are affected more often than men. The cause of CFS is unknown, although there are many theories ranging from viral infections to psychological stress. Some experts believe chronic fatigue syndrome might be triggered by a combination of factors.

20M

Estimated Patients 

75%

Unable To Work

24B$

US Economic Burden 

shutterstock_710229949_edited.jpg

Mild Cognitive Impairment  (MCI) 

Mild cognitive impairment (MCI) is the stage between the expected decline in memory and thinking that happens with age and the more serious decline of dementia. MCI may include problems with memory, language or judgment. People with MCI may be aware that their memory or mental function has "slipped." Family and close friends also may notice changes but these changes aren't bad enough to impact daily life or affect usual activities. MCI may increase the risk of dementia caused by Alzheimer's disease or other brain disorders.

12M

Estimated US Patients 

6-15%

Will Develop AD

2B$

Treatment  Market

bottom of page